Home > Business > Industry

Huons BioPharma picks new CEO

Published: 14 Apr. 2026, 20:10 Updated: 15 Apr. 2026, 10:47

이지원
[email protected]

Huons Global building in Gyeonggi [HUONS GLOBAL]

Huons BioPharma, a subsidiary of Huons Global, selected Lee Jeong-hee as its new CEO, the company said on Tuesday.

Born in 1976, Lee has over 23 years of experience in the domestic pharma market, including major companies such as Ipsen Korea, Han Wha Pharma, Hugel and Daewoong Pharmaceutical, according to the company. He joined the company this month.

With his expertise in pharmaceutical marketing and sales, Lee will aim to accelerate the company's global presence as its new leader.

In January this year, the company received marketing authorization in China to sell its product, Hutox, a product similar to Botox. It shipped its first batch last month.

Lee Jeong-hee, the new CEO of Huons BioPharma [HUONS GLOBAL]

"The company is at a crucial turning point to accelerate exports following the product approval in China," Lee said. “We will do our best to achieve sustainable growth by beginning full-scale market launch in China in the second half of this year and expanding research and development for next-generation products."

Huons BioPharma specializes in botulinum toxin products, injectables such as Botox, used in cosmetic procedures and medical treatments. It currently sells its products in 16 countries, including Thailand and Russia. It plans to expand global sales, focusing on markets such as South America, the Middle East, and Southeast Asia.

BY LEE JI-WON [[email protected]]